How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Antimicrobial Susceptibility Testing Instrument Market
- By Product Type: Automated AST Systems, Manual AST Systems, Semi-automated AST Systems, Molecular AST Instruments
- By Technology: Broth Microdilution, Disk Diffusion, Gradient Diffusion (E-test), Automated Microbial Identification and AST, Molecular Diagnostic Techniques
- By End User: Clinical Microbiology Laboratories, Hospital Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, Public Health Laboratories
- By Application: Bacterial Infection Diagnosis, Antibiotic Resistance Surveillance, Pharmaceutical Drug Development, Food Safety Testing, Environmental Microbiology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Automated AST Systems leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Antimicrobial Susceptibility Testing Instrument Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Technology 5
End User 5
Application 5
Companies profiled
bioMérieux
Thermo Fisher Scientific
BD (Becton
Dickinson and Company)
Siemens Healthineers
Accelerate Diagnostics
Liofilchem
Trek Diagnostic Systems (part of Thermo Fisher Scientific)
Beckman Coulter (a Danaher company)
Bruker Corporation
Copan Diagnostics
Hain Lifescience (a subsidiary of Bruker)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →bioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Accelerate Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Liofilchem
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Trek Diagnostic Systems (part of Thermo Fisher Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Beckman Coulter (a Danaher company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bruker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Copan Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hain Lifescience (a subsidiary of Bruker)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mérieux NutriSciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Oxoid (part of Thermo Fisher Scientific)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Micronaut (Bruker)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Autobio Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,431M by 2033 · 4.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Automated AST Systems50.0
- Manual AST Systems16.0
- Semi-automated AST Systems21.5
- Molecular AST Instruments12.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$546.4M → $715.4M · 3.4%
Europe$380.8M → $573.0M · 5.2%
Asia Pacific$347.7M → $500.9M · 4.7%
Latin America$215.2M → $301.1M · 4.3%
Middle East and Africa$165.6M → $225.1M · 3.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.872026
4.892027
4.902028
4.902029
4.922030
4.922031
4.942032
4.962033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- bioMérieux15.5
- Thermo Fisher Scientific20.1
- BD (Becton8.8
- Dickinson and Company)10.2
- Siemens Healthineers10.9
- Accelerate Diagnostics6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type20.8%
Technology33.2%
End User31.5%
Application14.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe24.7
- Asia Pacific21.6
- Latin America13.0
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| bioMérieux | 93 | 93 | 80 | 80 | 97 | 97 | 90 |
| Thermo Fisher Scientific | 72 | 69 | 78 | 90 | 85 | 69 | 77 |
| BD (Becton | 86 | 75 | 75 | 83 | 71 | 72 | 77 |
| Dickinson and Company) | 79 | 63 | 57 | 71 | 65 | 67 | 67 |
| Siemens Healthineers | 56 | 70 | 63 | 55 | 69 | 68 | 64 |
| Accelerate Diagnostics | 61 | 56 | 53 | 54 | 66 | 67 | 60 |
| Liofilchem | 43 | 62 | 61 | 62 | 53 | 46 | 55 |
| Trek Diagnostic Systems (part of Thermo Fisher Scientific) | 57 | 42 | 42 | 59 | 38 | 46 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- bioMérieux
- Thermo Fisher Scientific
- BD (Becton
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| bioMérieux | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| BD (Becton | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Dickinson and Company) | ◐ | − | − | ✓ | ◐ | − |
| Siemens Healthineers | − | ◐ | ◐ | ◐ | − | − |
| Accelerate Diagnostics | ◐ | ◐ | ◐ | − | − | ◐ |
| Liofilchem | − | ◐ | − | ◐ | ◐ | − |
| Trek Diagnostic Systems (part of Thermo Fisher Scientific) | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1bioMérieux90
2Thermo Fisher Scientific77
3BD (Becton77
4Dickinson and Company)67
5Siemens Healthineers64
6Accelerate Diagnostics60
7Liofilchem55
8Trek Diagnostic Systems (part of Thermo Fisher Scientific)47
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
bioMérieux
Challenger3
Strong scale, closing on the leaders.
Thermo Fisher ScientificBD (BectonDickinson and Company)
Contender2
Focused players with pockets of strength.
Siemens HealthineersAccelerate Diagnostics
Niche2
Specialists in a single segment or region.
LiofilchemTrek Diagnostic Systems (part of Thermo Fisher Scientific)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Antimicrobial Susceptibility Testing Instrument Market — a $497M beachhead inside a $7.71B market.
Beachhead (SOM)$497Mobtainable near-term
Serviceable (SAM)$3.02Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Automated AST Systems
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
Manual AST Systems
Strong fit — clear ROI and a fast path to value.
End user68 fit
Semi-automated AST Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Antimicrobial Susceptibility Testing Instrument Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation11%
Closed-won6%
$14.3KCAC
$74KLTV
5.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Antimicrobial Susceptibility Testing Instrument Market is a resilient opportunity — $622M by 2033, compounding at 5.3%.
TAM · 2025$413Mtoday
TAM · 2033$622Mforecast
CAGR5.3%2027–2033
Cumulative$4.60Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$622MTotal addressable market
SAM$221MServiceable available market
SOM$36MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$622MLarge & growingTAM by 2033 at 5.3% CAGR
$221MServiceable nowreachable with today’s model
$36MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$485MBear3.4% CAGR
$622MBase5.3% CAGR
$796MBull6.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Antimicrobial Susceptibility Testing Instrument Market — a $2.59B market by 2033. Plan: grow share from 11.7% to 18.8%.
Market size · 2033$2.59Btotal addressable
Market CAGR5.1%2027–2033
Target share18.8%from 11.7% today
Revenue ambition$487Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.7% | 18.8% | Ahead |
| Revenue | $314M | $487M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.1% | 42.1% | Behind |
| Customer retention | 87.8% | 95.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $62M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Antimicrobial Susceptibility Testing Instrument Market conversation — a $2.06B market you can size, segment and defend in minutes.
Market size · 2033$2.06Btotal opportunity
Growth5.2%CAGR to 2033
Addressable buyers1,331+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
bioMérieuxThermo Fisher ScientificBD (BectonDickinson and Company)Siemens HealthineersAccelerate DiagnosticsLiofilchemTrek Diagnostic Systems (part of Thermo Fisher Scientific)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Antimicrobial Susceptibility Testing Instrument Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Antimicrobial Susceptibility Testing Instrument Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Calcium Phosphate Bone Cement Market
Market size, share, segmentation and regional forecast.
$456M market · 2025 base year
View reportLaser Eye Shield Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportLaparoscopic Staplers Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportInsufflation Needles Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportHydroxyurea Market
Hydroxyurea Market is valued at USD 540 Million in 2025 and is expected to reach USD 695 Millio…
$540M market · 2025 base year
View reportHigh Potential Therapeutic Apparatus Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportHaemostat Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportGutta percha Root Canal Obturator Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportPeroxisome Proliferator Activated Receptor Delta Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportFluorescent Podoscopes Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportEnema Syringe Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportElectric Medical Bathtub Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.